• PDB91 - EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM

    Oct 1, 2018, 00:00

  • PRM106 - ADVANCED NMA TECHNIQUES IN NICE HTA SUBMISSIONS

    Oct 1, 2018, 00:00

  • PSY103 - MODELLING AVERAGE COST AND COST-PER-RESPONDER FOR BIOLOGICAL TREATMENTS FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS WITH DOSE ESCALATION AND REAL-WORLD DRUG SURVIVAL

    Oct 1, 2018, 00:00

  • PSS32 - COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

    Oct 1, 2018, 00:00

  • PCN331 - PERTUZUMAB RISK SHARING AGREEMENT IN THE PORTUGUESE NHS

    Oct 1, 2018, 00:00

  • ND1 - AMBULATORY FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY (DMD)- THE CHARACTERISTIC TRAJECTORY AND VARIATION ACROSS INDIVIDUALS

    Oct 1, 2018, 00:00

  • PIN67 - COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINATION IN GERMANY

    Oct 1, 2018, 00:00

  • PRM226 - DEVELOPMENT OF A METHOD FOR A STAR-SHAPED NETWORK META-ANALYSIS UNDER UNIDENTIFIABLE CONSISTENCY ASSUMPTION

    Oct 1, 2018, 00:00

  • PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLAND

    Oct 1, 2018, 00:00

  • PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE- MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGY

    Oct 1, 2018, 00:00

  • PMD101 - COST-EFFECTIVENESS OF TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT IN INTERMEDIATE-LOW RISK PATIENTS WITH SEVERE AORTIC STENOSIS IN SINGAPORE

    Oct 1, 2018, 00:00

  • PMS52 - COST-EFFECTIVENESS ANALYSIS OF TELEREHABILITATION FOR POST-ACUTE HIP ARTHROPLASTY- A DECISION MODEL

    Oct 1, 2018, 00:00

  • RM2 - MIXTURE METHODS INCORPORATING GENERAL POPULATION MORTALITY IN THE LIKELIHOOD FUNCTION OF PARAMETRIC DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations- The Effect on Patient-Reported Outcomes

    Oct 1, 2018, 00:00

  • PSY106 - COST-EFFECTIVENESS OF RARE DISEASES IN SPAIN

    Oct 1, 2018, 00:00

  • PSY42 - EXPLORING THE POTENTIAL BUDGET IMPACT OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY

    Oct 1, 2018, 00:00

  • PIN11 - HPV9-RELATED DISEASES- THE ECONOMIC BURDEN ON THE SOCIAL SECURITY SYSTEM IN ITALY

    Oct 1, 2018, 00:00

  • PCN213 - FINANCING EXPENSIVE ANTICANCER DRUGS IN HOSPITALS- TOWARDS TRANSPARENCY TO IMPROVE PATIENT ACCESS

    Oct 1, 2018, 00:00

  • PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTAT

    Oct 1, 2018, 00:00

  • PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICS

    Oct 1, 2018, 00:00

  • PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PMD65 - ECONOMIC VALUE OF NARROW BAND IMAGING VERSUS WHITE LIGHT ENDOSCOPY FOR THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER- COST-CONSEQUENCE MODEL

    Oct 1, 2018, 00:00

  • PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCER

    Oct 1, 2018, 00:00

  • PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD134 - MEDICAL DEVICE APPRAISAL IN THE UK- WHAT ARE THE COMMON PITFALLS OF MANUFACTURER LITERATURE REVIEWS?

    Oct 1, 2018, 00:00

  • PRM15 - PRE-APPROVAL SIMULATION OF REAL-WORLD OUTCOMES- DEVELOPMENT OF A METHODOLOGICAL FRAMEWORK

    Oct 1, 2018, 00:00

  • PCV57 - HEALTH INSURANCE COST OF HYPERTENSIVE HEART DISEASE IN HUNGARY- A NATIONWIDE COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PIN43 - A COST-EFFECTIVENESS ANALYSIS OF REVACCINATING OLDER ADULTS WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO VACCINATING WITH A SINGLE DOSE OF PPV23 IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PMU63 - EFFICIENCY ASSESSMENT IN PRIMARY HEALTHCARE CENTERS OF A HEALTH DISTRICT

    Oct 1, 2018, 00:00

  • PHP158 - DEMAND FOR SECOND OPINIONS IN THE PAEDIATRIC POPULATION- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PHP157 - APETITE FOR ON PATENTS- COST OF PRESCRIBING SWITCHING IN GREECE

    Oct 1, 2018, 00:00

  • PMS110 - RESEARCH APPLICATIONS OF PATIENT REPORTED OUTCOME MEASURES IN AN ACADEMIC ORTHOPAEDIC SURGERY DEPARTMENT

    Oct 1, 2018, 00:00

  • PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT- EXPERIENCES IN GERMANY 2018

    Oct 1, 2018, 00:00

  • PCV153 - ELICITING PUBLIC PREFERENCES FOR REORGANIZATION OF VASCULAR SERVICES IN THE UK

    Oct 1, 2018, 00:00

  • PRM23 - MODELLING CANCER TREATMENTS IN THE ADJUVANT SETTING- A TARGETED LITERATURE REVIEW (TLR) OF TECHNOLOGY APPRAISALS (TA) OF ADJUVANT THERAPIES SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND A CASE STUDY I ...

    Oct 1, 2018, 00:00

  • PDB106 - ASSESSING THE HEALTH AND ECONOMIC IMPACT OF PHARMACEUTICAL CARE IN ELDERLY PATIENTS WITH DIABETES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMU91 - USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015- NEUROLOGICAL DISORDERS

    Oct 1, 2018, 00:00

  • PHP102 - ARE SPECIFIC METHODOLOGICAL FRAMEWORKS REQUIRED FOR THE ECONOMIC EVALUATION OF GENE THERAPIES?

    Oct 1, 2018, 00:00

  • PSS2 - VALIDATION STUDY OF AN INFANTILE HEMANGIOMA (IH) SCORING TOOL FOR PRIMARY CLINICIANS TO IDENTIFY PATIENTS REQUIRING REFERRAL TO EXPERT CENTERS

    Oct 1, 2018, 00:00

  • PIN116 - PRIORITIZING INVESTMENTS IN NEW VACCINES AGAINST EPIDEMIC INFECTIOUS DISEASES- A MULTI-CRITERIA DECISION ANALYSIS

    Oct 1, 2018, 00:00

  • PRM174 - OPERATING SYSTEM UPGADES DO NOT ADVERSELY AFFECT ECOA COMPLETION BEHAVIOR WHEN USING A BRING YOUR OWN DEVICE (BYOD) APP.

    Oct 1, 2018, 00:00

  • PIH46 - ANALYSING THE ATTITUDE OF OLD AGE HOME RESIDENTS ON POLYPHARMACY AND DEPRESCRIBING OF MEDICATIONS IN MANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PSY13 - THE TREATMENT OPTIONS FOR ACUTE ATTACK OF HEREDITARY ANGIOEDEMA (HAE)- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOL

    Oct 1, 2018, 00:00

  • PCN194 - COST-EFFECTIVENESS OF SCALING-UP CERVICAL CANCER SCREENING RATES AND HPV VACCINE INITIATION IN TURKEY

    Oct 1, 2018, 00:00

  • PCN118 - THE BURDEN OF CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PIN13 - THE INCIDENCE OF SURGICAL SITE INFECTION IN POLAND

    Oct 1, 2018, 00:00

  • PIN87 - PHYSICIAN PREFERENCES FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION- AN ADAPTIVE CONJOINT ANALYSIS

    Oct 1, 2018, 00:00

  • PHP11 - HOW TO RESOLVE ISSUES EXPERIENCED BY PATIENTS IN EARLY PHASE DEVELOPMENT OF PHARMACEUTICAL PRODUCTS

    Oct 1, 2018, 00:00

  • PSS48 - PARENTS’ BELIEFS AND KNOWLEDGE ABOUT THE MANAGEMENT OF OTITIS MEDIA IN UNAIZAH, SAUDIARABIA- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PMH55 - A COMPARISON OF PATIENTS PRESCRIBED ANTIPSYCHOTICS FOR PARKINSON’S DISEASE WITH PSYCHOSIS USING ADMINISTRATIVE CLAIMS DATA FROM A LARGE U.S. INSURER

    Oct 1, 2018, 00:00

  • PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PDB93 - IMPACT OF CARDIOVASCULAR DISEASE ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTING

    Oct 1, 2018, 00:00

  • PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?

    Oct 1, 2018, 00:00

  • PIN55 - COST-EFFECTIVENESS ANALYSIS OF INFANT FORMULA SUPPLEMENTED WITH HUMAN MILK OLIGOSACCHARIDE (HMO) IN THE PREVENTION OF LOWER RESPIRATORY TRACT INFECTIONS IN MEXICO AND CHINA

    Oct 1, 2018, 00:00

  • PCN247 - TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERA

    Oct 1, 2018, 00:00

  • PSS35 - SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND125 - THE ASSOCIATION BETWEEN UTILITIES AND DISEASE SEVERITY FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP64 - ALLOWABILITY OF OUTCOMES-BASED RISK-SHARING SCHEMES IN RUSSIA WITHIN CURRENT LEGISLATIVE HURDLES

    Oct 1, 2018, 00:00

  • PCV21 - IMPACT OF GENETIC AND NON-GENETIC FACTORS ON CLOPIDOGREL EFFICACY

    Oct 1, 2018, 00:00

  • PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONS

    Oct 1, 2018, 00:00

  • PUK1 - DR RAJA AHSAN AFTAB

    Oct 1, 2018, 00:00

  • PMS103 - IMPACT OF PHYSICAL FUNCTIONING ON THE QUALITY OF LIFE AFTER TOTAL KNEE REPLACEMENT

    Oct 1, 2018, 00:00

  • PMU38 - REVIEW OF STUDIES REPORTING ACTUAL PRICES FOR MEDICINES

    Oct 1, 2018, 00:00

  • PIN56 - COST-EFFECTIVENESS OF VARICELLA AND HERPES ZOSTER VACCINATION IN THE SWEDISH POPULATION

    Oct 1, 2018, 00:00

  • PRM127 - ECONOMIC MODELLING CONSIDERATIONS IN RARE DISEASES- A TARGETED REVIEW OF HIGHLY SPECIALISED TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PRS38 - COST-CONSEQUENCE ANALYSIS OF FLUTICASONE FUROATE/VILANTEROL FOR ASTHMA MANAGEMENT IN SPAIN- AN ANALYSIS BASED ON THE SALFORD LUNG STUDY IN ASTHMA

    Oct 1, 2018, 00:00

  • PHP331 - IS IT ENOUGH TO HAVE IT IN THE VACCINATION PROGRAMME? AN EMPIRICAL ANALYSIS OF THE FACTORS THAT AFFECT INFLUENZA VACCINATION UPTAKE IN ADULTS IN GREECE

    Oct 1, 2018, 00:00

  • PHP235 - INDIRECT TREATMENT COMPARISONS (ITC) FOR HTA IN EUROPE – UNDERSTANDING REQUIREMENTS FOR INDUSTRY SUBMISSIONS

    Oct 1, 2018, 00:00

  • PSS57 - TREATMENT OF ATOPIC DERMATITIS IN PORTUGAL- INSIGHTS FROM A PHYSICIANS’ SURVEY

    Oct 1, 2018, 00:00

  • PMS19 - A BUDGET IMPACT ANALYSIS OF INTRODUCING A FORCED TREATMENT PATHWAY USING THE LOWEST PRICED ANTI-TUMOR NECROSIS FACTOR AGENT FOR RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN THE PHILIPPINES

    Oct 1, 2018, 00:00

  • PSY189 - TREATMENT GUIDELINE INCLUDING THE HEALTH ECONOMIC EVALUATIONS OF BIOLOGIC DRUGS USED FOR PSORIATIC ARTHRITIS- PICOSTEPS, SYSTEMATIC LITERATURE REVIEW, APPLICABILITY EVALUATION AND LEVEL OF EVIDENCE EVALUATION

    Oct 1, 2018, 00:00

  • PCV131 - IMPACT OF TIMELY INITIATION OF ANTIHYPERTENSIVE MEDICATIONS FOR PATIENTS WITH HYPERTENSION OR ELEVATED BLOOD PRESSURE

    Oct 1, 2018, 00:00

  • PRS83 - PATIENT PERSPECTIVE ON MEDICATION ADHERENCE IN ASTHMA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PSY96 - COST-EFFECTIVENESS OF ORIGINATOR ADALIMUMAB IN NON-INFECTIOUS INTERMEDIATE, POSTERIOR AND PAN-UVEITIS FROM A SOCIETAL PERSPECTIVE IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH- WHAT CAN BE LEARNED?

    Oct 1, 2018, 00:00

  • PCN36 - THE EFFECT OF INTRODUCING NIVOLUMAB IN THE ADJUVANT TREATMENT SETTING OF MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PHP267 - LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPE

    Oct 1, 2018, 00:00

  • PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDREN

    Oct 1, 2018, 00:00

  • PRM193 - FROM INDIVIDUAL PATIENT TO POPULATION PREFERENCES- MULTINOMIAL LOGIT MODEL VS DIRICHLET DISTRIBUTION

    Oct 1, 2018, 00:00

  • PSS67 - UNDERSTANDING THE PATIENT EXPERIENCE OF PRESBYOPIA AND IDENTIFICATION OF PATIENT-REPORTED OUTCOME ASSESSMENTS- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB5 - EFFECT OF STATINS USAGE ON INCIDENCE OF PERIPHERAL NEUROPATHY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?

    Oct 1, 2018, 00:00

  • PSY58 - BUDGET IMPACT ANALYSIS OF EMICIZUMAB IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS IN THE MINISTRY OF HEALTH (MOH), KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PCN363 - A BEST–WORST SCALING SURVEY OF PREFERENCES OF CURRENT, PAST AND NEVER SMOKERS FOR ADVERSE EFFECTS OF SMOKING IN JAPAN

    Oct 1, 2018, 00:00

  • PGI33 - URSODEOXYCHOLIC ACID TO GALLSTONE DISSOLUTION THERAPY IN ASYMPTOMATIC CHOLELITHIASIS PATIENTS- A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY

    Oct 1, 2018, 00:00

  • PRM98 - FACTORS ASSOCIATED WITH THE INCIDENCE OF ONCOLOGY DRUGS SHORTAGES IN THE UNITED STATES (2001-2017)

    Oct 1, 2018, 00:00

  • PMU4 - THE SAFETY OF SWITCHING BETWEEN REFERENCE BIOPHARMACEUTICALS AND BIOSIMILARS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSY9 - REAL-WORLD EPIDEMIOLOGY, TREATMENT PATTERNS AND SURVIVAL OF MULTIPLE MYELOMA PATIENTS IN A LARGE NATIONWIDE HEALTH PLAN

    Oct 1, 2018, 00:00

  • PIH31 - USE OF ADMINISTRATIVE DATA FOR ASSESSMENT OF MEDICATION PRESCRIPTION PRACTICE IN TWO ITALIAN SETTINGS

    Oct 1, 2018, 00:00

  • PND67 - ARE NEW PREVENTIVE MIGRAINE DRUGS COST-EFFECTIVE FOR PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE FOR WHOM OTHER PREVENTIVE MEDICATIONS HAD FAILED?

    Oct 1, 2018, 00:00

  • PMU126 - SUBJECTIVE EXPECTATIONS REGARDING FUTURE HEALTH, WELL-BEING AND HEALTHCARE COSTS IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN127 - DIRECT HEALTHCARE COSTS BY TREATMENT AMONG PATIENTS WITH MERKEL CELL CARCINOMA (MCC) IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTS

    Oct 1, 2018, 00:00

  • PRS17 - BUDGET IMPACT ANALYSIS OF THE USE OF UMECLIDINIUM BROMIDE/VILANTEROL 62.5/25 MCG IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

    Oct 1, 2018, 00:00

  • PIH26 - PRACTICE TOWARD ANTIBIOTICS PREPARATION AMONG IRANIAN PARENTS

    Oct 1, 2018, 00:00

  • PMU76 - PATIENT SATISFACTION FROM INSTRUCTIONS OF COLONOSCOPY PREPARATION AND COST ASSESSMENT OF INADEQUATE BOWEL PREPARATION

    Oct 1, 2018, 00:00

  • PMD159 - ASSESSMENT OF THE MARKET ACCESS POTENTIAL OF A NOVEL MEDICAL DEVICE AND APP COMBINATION FOR AN ORPHAN DISEASE

    Oct 1, 2018, 00:00

  • PMH3 - COMPARING THE RISK OF SUICIDALITY IN ADULT VERSUS YOUTH PATIENTS TREATED WITH SEROTONIN REUPTAKE INHIBITORS - A REAL-WORLD EVIDENCE-BASED APPROACH

    Oct 1, 2018, 00:00

  • PCN340 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (VMP) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) INELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES

    Oct 1, 2018, 00:00

  • PRS12 - DEVELOPMENT AND VALIDATION OF AN ALGORITHM IDENTIFYING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN HOSPITAL DISCHARGE DATABASES

    Oct 1, 2018, 00:00

  • PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY- THE SAMANTA QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PCN42 - EFFICACY OF THIRD LINE TYROSINE KINASE INHIBITORS FOR TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOURS- SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP325 - ORPHAN DRUGS‘ MARKET ACCESS CHALLENGES IN EUROPE FROM A GERMAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN379 - QUANTITATIVE COMPARISON OF THE INFLUENCE OF OPEN LABEL TRIAL DESIGN ON PATIENT REPORTED OUTCOME RESPONSES – A METASTATIC MELANOMA CASE STUDY.

    Oct 1, 2018, 00:00

  • PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PMU52 - COST IN COMPLEX ABDOMINAL OPERATIONS IN PUBLIC HEALTH INSURANCE PERSPECTIVE FOR TURKEY

    Oct 1, 2018, 00:00

  • PCV52 - COST COMPARISON- STRATEGIES OF PATIENTS MANAGEMENT IN ORAL ANTICOAGULANT THERAPY

    Oct 1, 2018, 00:00

  • PDB104 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF DIABETES IN EGYPT

    Oct 1, 2018, 00:00

  • PHP350 - PERFORMANCE AND OUTCOMES BASED CONTRACTS IN THE EU AND USA- COMPARISON OF TRENDS AND RECENT DEVELOPMENTS

    Oct 1, 2018, 00:00

  • PHP37 - SPEEDING TO MARKET? AN EVALUATION OF ACCELERATED DRUG APPROVAL PATHWAYS IN AUSTRALIA, CANADA, AND SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PSY192 - PATIENT HEALTH-RELATED QUALITY OF LIFE ASSOCIATED WITH REMISSION OF ATTP, A REGRESSION ANALYSIS USING NON-RANDOMISED OBSERVATIONAL DATA FROM THE OKLAHOMA TTP REGISTRY

    Oct 1, 2018, 00:00

  • PCP42 - ECONOMIC EVALUATION OF INTELLIGENT ROLLATORS – ESTIMATING THEIR BENEFITS

    Oct 1, 2018, 00:00

  • PND15 - TREATMENT AND CHARACTERISTICS OF PEDIATRIC PATIENTS WITH FOCAL EPILEPSY IN GERMANY

    Oct 1, 2018, 00:00

  • PHP182 - EXTERNAL REFERENCE PRICING- CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVER

    Oct 1, 2018, 00:00

  • PCV36 - ESTIMATION OF THE INCREASED RISK ASSOCIATED WITH RECURRENT EVENTS OR POLY-VASCULAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN THE UNITED KINGDOM FOR USE IN ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PCN353 - CONSTRUCT VALIDITY OF EQ-5D-3L IN NON-MELANOMA SKIN CANCER (NMSC)

    Oct 1, 2018, 00:00

  • PMU114 - COMPARING A DIRECT AND STAGED APPROACH TO ITEM SELECTION IN A MULTI-DIMENSIONAL PATIENT-REPORTED OUTCOME MEASURE

    Oct 1, 2018, 00:00

  • PCP5 - THE ECOLOGICAL AND SOCIAL COSTS AND BENEFITS OF INTERVENTIONS – USING THE PRODUCT CARBON FOOTPRINT IN VALUE ASSESSMENT

    Oct 1, 2018, 00:00

  • PMU13 - REALIZING TRANSPARENCY- REGISTRATION OF REAL-WORLD EVIDENCE STUDIES OF TREATMENT AND/OR COMPARATIVE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PND2 - RISK OF PARKINSON’S DISEASE (PD) IN PATIENTS TAKING ADRENERGIC DRUG TREATMENTS

    Oct 1, 2018, 00:00

  • PSY223 - QUALITATIVE RESEARCH IN HAEMOPHILIA A- EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

    Oct 1, 2018, 00:00

  • PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMH6 - LURASIDONE INDUCED SUICIDAL IDEATION AND HALLUCINATION- DISPROPORTIONALITY ANALYSIS IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PHP358 - TIME-LIMITED G-BA RESOLUTIONS – A TOOL TO APPROPRIATELY MANAGE REIMBURSEMENT OF INNOVATIVE THERAPIES RECEIVING EXPEDITED REGULATORY APPROVAL

    Oct 1, 2018, 00:00

  • PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL

    Oct 1, 2018, 00:00

  • PRM78 - TECHNIQUES FOR PREVENTION AND DETECTION OF FRAUD IN RANDOMISED CONTROLLED TRIALS BASED ON ROUTINELY COLLECTED ELECTRONIC HEALTH RECORDS

    Oct 1, 2018, 00:00

  • PIN104 - MENINGOCOCCAL GROUP B (MENB) VACCINE SERIES COMPLETION AND COMPLIANCE AMONG COMMERCIALLY-INSURED INDIVIDUALS AGED 16-23 IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PIN85 - TENOFOVIR ALAFENAMIDE’S IMPACT ON COMORBIDITIES AMONG PEOPLE LIVING WITH HIV IN PORTUGAL- A SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PSY19 - USING A BAYESIAN NETWORK META-ANALYSIS (NMA) TO COMPARE FERRIC MALTOL TO TREATMENTS FOR IRON DEFICIENCY AND IRON DEFICIENCY ANAEMIA EXCLUDING CHF AND CKD PATIENTS

    Oct 1, 2018, 00:00

  • PSS1 - SYSTEMATIC REVIEWS OF OPHTHALMIC ADVERSE DRUG REACTIONS PUBLISHED IN OPHTHALMOLOGY JOURNALS- A METHODOLOGICAL ASSESSMENT

    Oct 1, 2018, 00:00

  • PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECE

    Oct 1, 2018, 00:00

  • PCP11 - ORGANISATIONAL MODELS AND OPPORTUNITIES FOR EFFICIENCY MEASURING IN HEALTH CARE

    Oct 1, 2018, 00:00

  • PHP161 - ASSESSING THE NET PRICE LEVEL OF GENERICS IN GREECE- THE EFFECT OF COMPULSORY PAYBACKS

    Oct 1, 2018, 00:00

  • PDB38 - BUDGET IMPACT ANALYSIS OF BENAGLUTIDE INJECTION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINA

    Oct 1, 2018, 00:00

  • PND60 - COST-EFFECTIVENESS OF TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PCN129 - TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN176 - A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM

    Oct 1, 2018, 00:00

  • PIN42 - DETERMINATING THE ACCEPTABLE PRICE FOR QUADRIVALENT INFLUENZA VACCINE IN RUSSIA

    Oct 1, 2018, 00:00

  • PMH1 - PATIENT-REPORTED SIDE EFFECTS OF BUPRENORPHINE-NALOXONE- IDENTIFYING INDEPENDENT PREDICTORS FROM PATIENT VIEWS AND CLINICAL ASSESSMENT DURING MAINTENANCE TREATMENT OF HEROIN USE DISORDER

    Oct 1, 2018, 00:00

  • PIN38 - CLINICAL AND ECONOMIC IMPACT OF THE TREATMENT OF CHRONIC HEPATITIS C IN PRISON INMATES IN SPAIN

    Oct 1, 2018, 00:00

  • PRM35 - INCREMENTAL COST EFFECTIVENESS RATIO (ICER) THRESHOLD, THE END OF HORIZONTAL EQUITY?

    Oct 1, 2018, 00:00

  • PND85 - PROPHYLACTIC MIGRAINE MEDICATION USE IN PRIMARY CARE SETTING IN FINLAND

    Oct 1, 2018, 00:00

  • PND29 - LONG RANGE SIMULATION OF THE COST BURDEN OF DIFFERENCE TREATMENT SEQUENCES APPROVED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PND117 - PHYSICIAN REPORTED ADHERENCE IN MS PATIENTS TREATED WITH INJECTABLE PLATFORM THERAPIES VERSUS DELAYED-RELEASE DIMETHYL FUMARATE- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • Assessing Rationality in Discrete Choice Experiments in Health- An Investigation into the Use of Dominance Tests

    Oct 1, 2018, 00:00

  • PDB123 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH TYPE 1 DIABETES? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)

    Oct 1, 2018, 00:00

  • PSY32 - CLAIMS-BASED ANALYSIS OF HOMOCYSTEINE TESTING, ELEVATED HOMOCYSTEINE LEVELS, AND HOMOCYSTINURIA DIAGNOSIS IN THE U.S.

    Oct 1, 2018, 00:00

  • PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC- COMPARISON OF VALUE TO PRICE

    Oct 1, 2018, 00:00

  • PMS81 - CONSENSUS ON THE MEASUREMENT INSTRUMENTS TO EVALUATE THE EFFECTIVENESS OF BIOLOGICAL TREATMENT IN PSORIATIC ARTHRITIS- MERECES STUDY.

    Oct 1, 2018, 00:00

  • PMD19 - EFFECTIVENESS OF REAL-TIME POLYMERASE CHAIN REACTION FOR THE DIAGNOSIS AND MONITORING OF ADENOVIRUS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN111 - COST ESTIMATE OF IMMUNE-RELATED ADVERSE REACTIONS ASSOCIATED WITH INNOVATIVE TREATMENTS OF METASTATIC MELANOMA

    Oct 1, 2018, 00:00

  • PMD30 - BUDGET IMPACT ANALYSIS OF ROUTINE ADOPTION OF NON-INVASIVE PRENATAL TESTING (NIPT) IN DIFFERENT RISK-SCORE PREGNANCY POPULATIONS IN THE UK

    Oct 1, 2018, 00:00

  • PSY90 - RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE DATA TO ASSESS ADHERENCE, PHARMACOUTILIZATION AND COSTS OF BIOLOGICAL THERAPY TREATMENT OF PSORIASIS IN SOUTHERN ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PCN358 - SATISFACTION WITH HEALTH CARE ANALYSIS IN CERVIX-UTERI CANCER MEXICAN WOMEN TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PUK2 - PREDICTORS FOR BLOOD PRESSURE CONTROL AMONG POST DIALYSIS HYPERTENSIVE PATIENTS WHEN TREATED WITH AND WITHOUT RAAS INHIBITOR

    Oct 1, 2018, 00:00

  • PMD155 - IMPACT OF MINIMALLY INVASIVE TREATMENTS FOR PERIPHERAL ARTERIAL DISEASE IN HUNGARY

    Oct 1, 2018, 00:00

  • PMU75 - IS ADOPTING A LOW PRICE STRATEGY TO GAIN MARKET ACCESS COMPATIBLE WITH A VIABLE GENE/CELL THERAPY BUSINESS?

    Oct 1, 2018, 00:00

  • PMD53 - REMOVABLE DINOPROSTONE VAGINAL DELIVERY SYSTEM- COST-CONSEQUENCES MODEL FOR CENTRAL AND EASTERN EUROPE COUNTRIES

    Oct 1, 2018, 00:00

  • PMS30 - COST ANALYSIS FOR DIFFERENT ANTI-RHEUMATOID BIOLOGICAL TREATMENTS AFTER FAILURE OF CONVENTIONAL DMARDS IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PCN184 - COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PIN40 - COST-EFFECTIVENESS OF FIRST-LINE TREATMENT FOR INVASIVE ASPERGILOSIS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PCN241 - OLAPARIB USE AND TREATMENT OUTCOMES IN SWEDISH PATIENTS TREATED DURING THE FIRST THREE YEARS FOLLOWING REGULATORY APPROVAL

    Oct 1, 2018, 00:00

  • PMD168 - MARKET ACCESS FOR COMPANION DIAGNOSTICS IN ONCOLOGY IN THE EU5 AND ASIA-PACIFIC REGION

    Oct 1, 2018, 00:00

  • PIN14 - BIOMEDICAL AND THERAPEUTIC PREDICTORS OF SURVIVAL TIME AND MORTALITY OF ADULT HIV/TB CO-INFECTIONS; A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PMD69 - SYSTEMATIC REVIEW AND ECONOMIC ANALYSIS OF ANTISEPTIC BARRIER CAPS IN PATIENTS WITH CENTRAL OR PERIPHERAL LINE CATHETERS

    Oct 1, 2018, 00:00

  • PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMES

    Oct 1, 2018, 00:00

  • PCN253 - DID THE EUROPEAN FINANCIAL CRISIS HAVE AN IMPACT ON ECONOMIC DECISION-MAKING IN HEALTH TECHNOLOGY ASSESSMENTS?

    Oct 1, 2018, 00:00

  • PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP133 - TOWARDS IMPLEMENTING MEDICATION THERAPY MANAGEMENT SERVICE IN MALAYSIA- PERCEPTIONS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PHP269 - DESIGN AND EVALUATION OF MALAYSIAN MODEL OF PHARMACEUTICAL PICTOGRAMS

    Oct 1, 2018, 00:00

  • PCN8 - SEVERITY OF BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES AND NOT WITH INSULIN TREATMENT

    Oct 1, 2018, 00:00

  • PHP369 - CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ADVANCED THERAPIES IN EUROPE- A CASE STUDY

    Oct 1, 2018, 00:00

  • PMU59 - ARE THERE ANY IMPLICIT GUIDELINES FOR INCLUDING ADVERSE EVENTS IN COST-EFFECTIVENESS MODELS INTENDED FOR FRENCH HEALTH AUTHORITIES? AN ANALYSIS OF EFFICIENCY OPINIONS

    Oct 1, 2018, 00:00

  • PDB37 - BUDGET IMPACT ANALYSIS OF THE ADULT TYPE 1 DIABETES MELLITUS NATIONAL CLINICAL GUIDELINE IN IRELAND

    Oct 1, 2018, 00:00

  • PDB60 - COST-CONSEQUENCE ANALYSIS FOR RECOMBINANT HUMAN GROWTH HORMONE TREATMENT ADMINISTERED VIA DIFFERENT DEVICES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN ITALY

    Oct 1, 2018, 00:00

  • PMH15 - A NETWORK META-ANALYSIS OF MEDICINES USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS

    Oct 1, 2018, 00:00

  • PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

    Oct 1, 2018, 00:00

  • PMS53 - VALIDATION IN A REAL WORLD SCENARIO OF A CLINICAL DECISION SUPPORT SYSTEM FOR THE PREVALENCE, FRACTURE RISKS AND TREATMENT OF OSTEOPOROSIS IN THE BRAZILIAN PRIVATE MARKET

    Oct 1, 2018, 00:00

  • PSY139 - CURRENT USE OF FACTOR VIII PRODUCTS IN CHILDREN AND ADOLESCENTS WITH MODERATE OR SEVERE HAEMOPHILIA A

    Oct 1, 2018, 00:00

  • PSY164 - DRIVERS OF ORPHAN MEDICINAL PRODUCT VALUE, PRICE AND COSTS – A PRACTICAL EXPLORATORY ANALYSIS

    Oct 1, 2018, 00:00

  • PSY191 - HEALTH STATE UTILITIES ASSOCIATED WITH TREATMENT FOR TRANSFUSION DEPENDENT B-THALASSEMIA

    Oct 1, 2018, 00:00

  • PCP29 - BRAZILIAN PHARMACEUTICAL CLINICAL SERVICES- A DOCUMENTARY ANALYSIS

    Oct 1, 2018, 00:00

  • PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISON

    Oct 1, 2018, 00:00

  • PCN2 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC MELANOMA- PRELIMINARY RESULTS FROM REAL WORLD

    Oct 1, 2018, 00:00

  • PMD50 - MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND VERSUS DEEP BRAIN STIMULATION IN MEDICALLY-REFRACTORY ESSENTIAL TREMOR- A COST-CONSEQUENCE ANALYSIS IN THE UK SETTING

    Oct 1, 2018, 00:00

  • PSY165 - PRICE DIFFERENCES FOR ORPHAN DRUGS ACROSS THE EU-5 COUNTRIES- A COMPARATIVE ASSESSMENT

    Oct 1, 2018, 00:00

  • PHP360 - THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKING

    Oct 1, 2018, 00:00

  • PCV86 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2018, 00:00

  • PIH38 - PREVALENCE OF PELVIC FLOOR DISORDERS AMONG WOMEN IN EASTERN REGION OF NEPAL

    Oct 1, 2018, 00:00

  • PCN373 - UNDERSTANDING PATIENT PERSPECTIVES OF RENAL CELL CARCINOMA USING SOCIAL MEDIA- A QUALITATIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PCP39 - INNOVATION IN IDENTIFYING BARRIERS TO ACCESS AND IMPROVING THE QUALITY OF CANCER CARE AND TREATMENT FOR VULNERABLE AREAS PEOPLE, ARGENTINA 2017

    Oct 1, 2018, 00:00

  • PMS102 - THE RELATION BETWEEN TRAINING METHODS AND FORMED INJURIES AMONG PEOPLE DOING WEIGHT TRAINING

    Oct 1, 2018, 00:00

  • PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).

    Oct 1, 2018, 00:00

  • PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKS

    Oct 1, 2018, 00:00

  • PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTING

    Oct 1, 2018, 00:00

  • PND34 - PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Oct 1, 2018, 00:00

  • PDB121 - QUALITY OF LIFE AND UTILITY VALUES FOR COST-EFFECTIVENESS MODELING IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCV142 - ADHERENCE TO ORAL ANTICOAGULATION TREATMENT IN ATRIAL FIBRILLATION AND THE IMPACT OF PATIENT SATISFACTION

    Oct 1, 2018, 00:00

  • PCN282 - CANCER DRUGS FUND (CDF) IN THE UNITED KINGDOM- A 2-YEAR ANALYSIS

    Oct 1, 2018, 00:00

  • PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY- APPROVAL CONDITIONS (2015-2018)

    Oct 1, 2018, 00:00

  • PCN336 - TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PIH11 - ANTIEMETIC USE IN PREGNANCY AND THE RISK OF MAJOR CONGENITAL MALFORMATIONS- A POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PHP165 - THE LONG-TERM CHANGE OF MEDICAL SERVICE PRICE- AN INTERNATIONAL COMPARISON OF SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELING

    Oct 1, 2018, 00:00

  • PMD135 - DETERMINING FACTORS FOR DECISION-MAKING IN THE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME

    Oct 1, 2018, 00:00

  • PRS80 - HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR NOVEL ASTHMA THERAPIES- RESULTS, RATIONALE, AND TRENDS

    Oct 1, 2018, 00:00

  • PMU106 - CHOOSING VIDEO INSTEAD OF IN-CLINIC CONSULTATIONS IN PRIMARY CARE- DISCRETE CHOICE EXPERIMENT AMONG KEY STAKEHOLDERS- PATIENTS, PRIMARY CARE PRACTITIONERS AND POLICY MAKERS

    Oct 1, 2018, 00:00

  • PRS99 - IMPACT OF COUGH AND MUCUS ON THE EMOTIONAL AND PSYCHOSOCIAL WELLBEING IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE- A QUALITATIVE PATIENT ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PHP352 - SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTS

    Oct 1, 2018, 00:00

  • PMU61 - BEYOND THE COST-EFFECTIVENESS ACCEPTABILITY CURVE- THE APPROPRIATENESS OF RANK PROBABILITIES FOR PRESENTING THE RESULTS OF ECONOMIC EVALUATION IN MULTIPLE TECHNOLOGY APPRAISAL

    Oct 1, 2018, 00:00

  • PRM276 - METHODOLOGICAL ISSUES OF DRUG PRICE COMPARISON STUDIES- WHAT IMPROVEMENT IN QUALITY?

    Oct 1, 2018, 00:00

  • PGI31 - PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION- REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAEL

    Oct 1, 2018, 00:00

  • PSY50 - BUDGET-IMPACT ANALYSIS (BIA) OF CHRONIC PAIN SYNDROMES FROM A HEALTHCARE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PSY56 - COST-UTILITY OF NEW FILM-COATED TABLET FORMULATION OF DEFERASIROX VERSUS DEFEROXAMINE AMONG MAJOR B-THALASSEMIA PATIENTS IN IRAN

    Oct 1, 2018, 00:00

  • PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES- IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENT

    Oct 1, 2018, 00:00

  • PIN9 - NOVEL APPROACH FOR INFLUENZA VACCINATION- APPLICATION OF AN EMERGING TECHNOLOGIES EVALUATION STRATEGY

    Oct 1, 2018, 00:00

  • PHP58 - SPANISH THERAPEUTIC POSITIONING REPORTS- 6-YEAR UPDATE – INCREASING IN FREQUENCY BUT NOT RELEVANCE?

    Oct 1, 2018, 00:00

  • PRM214 - DO UTILITY VALUES USED IN HEALTH TECHNOLOGY ASSESSMENT MAINLY COME FROM WIDELY CITED REFERENCES?

    Oct 1, 2018, 00:00

  • PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAEL

    Oct 1, 2018, 00:00

  • PCN279 - A REVIEW OF RECOMMENDATIONS FOR INCLUSION AND DATA COLLECTION WITHIN THE CDF FRAMEWORK

    Oct 1, 2018, 00:00

  • RM3 - IS PATIENT CHOICE PREDICTABLE? THE IMPACT OF DISCRETE CHOICE EXPERIMENT DESIGNS AND MODELS

    Oct 1, 2018, 00:00

  • PSY205 - BODY IMAGE IN SLE AND THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND PSYCHOSOCIAL CONCERNS

    Oct 1, 2018, 00:00

  • PCP2 - IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION-MAKERS- A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS.

    Oct 1, 2018, 00:00

  • PMD103 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING LEG ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PSY202 - THE OCCUPATIONAL HAZARDS OF MEASURING RISK TOLERANCE- CONVERGENT VALIDITY IN PREFERENCE ELICITATION.

    Oct 1, 2018, 00:00

  • PRM177 - CAN THE EQ-5D HELP UNDERSTAND HOW CHANGES IN CLINICAL OUTCOMES IMPACT ON DIFFERENT CONCEPTS OF HEALTH?

    Oct 1, 2018, 00:00

  • PMS118 - QUALITY OF LIFE OF DUPUYTREN’S DISEASE PATIENTS TREATED WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM- A PROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS- EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMAB

    Oct 1, 2018, 00:00

  • PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO

    Oct 1, 2018, 00:00

  • PCN195 - COST-UTILITY ANALYSIS OF THE GERMLINE BRCA TESTING IN WOMEN WITH EPITHELIAL OVARIAN CANCER WITHOUT FAMILY HISTORY IN SPAIN

    Oct 1, 2018, 00:00

  • PCV116 - DISCONTINUATION AND HEALTH CARE RESOURCE UTILISATION IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN OR WARFARIN IN ENGLAND

    Oct 1, 2018, 00:00

  • PMD66 - COMPARING THE LONG-TERM IMPACT ON HEALTHCARE RESOURCES AND COSTS DUE TO SINGLE-PIECE ACRYLIC INTRAOCULAR LENS (IOLS) IMPLANTATION DURING CATARACT SURGERY- A COST-CONSEQUENCE ANALYSIS FROM UK HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?

    Oct 1, 2018, 00:00

  • PRM64 - THE NEED FOR INNOVATIVE SURVIVAL MODELLING APPROACHES IN HEALTH TECHNOLOGY ASSESSMENTS (HTA) OF EARLY-STAGE ONCOLOGY INDICATIONS

    Oct 1, 2018, 00:00

  • PMD22 - THE EFFECTIVENESS OF ELECTRONIC LARYNX FOR SPEECH REHABILITATION OF LARINGECTOMIZED PATIENTS- A REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PSS72 - FAMILY PSO- IMPACT OF PSORIASIS ON THE PARTNER

    Oct 1, 2018, 00:00

  • PSY166 - MARKET ACCESS TRENDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN EUROPE

    Oct 1, 2018, 00:00

  • PND76 - THE ECONOMIC CONSEQUENCES OF BENEFITS OF DELAYED-RELEASE DIMETHYL FUMARATE TREATMENT VERSUS BETA INTERFERONS AND GLATIRAMER ACETATE ON ABILITY TO WORK OF MULTIPLE SCLEROSIS PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PMU82 - SOCIOECONOMIC AND HEALTH-RELATED FACTORS ASSOCIATED WITH ADHERENCE TO CHRONIC MEDICATION IN GREECE

    Oct 1, 2018, 00:00

  • PSY214 - PHYSICAL ACTIVITY AND QUALITY OF LIFE OUTCOMES IN MULTIPLE MYELOMA PATIENTS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSS27 - A COST-EFFECTIVENESS ANALYSIS OF TWO VISUAL ACUITY CUTOFFS FOR CATARACT SURGERY IN PATIENTS WITH PSEUDOEXFOLIATION IN UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMD42 - ECONOMIC IMPACT OF LAPAROSCOPIC VS OPEN SURGERY FOR COLORECTAL CANCER- A BUDGET IMPACT ANALYSIS IN ITALY

    Oct 1, 2018, 00:00

  • Accuracy of Linking VR-12 and PROMIS Global Health Scores in Clinical Practice

    Oct 1, 2018, 00:00

  • CV2 - IMPACT OF ATRIAL FIBRILLATION (AF) AWARENESS CAMPAIGNS ON RATES OF AF RELATED CONSULTATIONS IN UK PRIMARY CARE- INTERRUPTED TIME SERIES ANALYSES.

    Oct 1, 2018, 00:00

  • PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATION

    Oct 1, 2018, 00:00

  • PRM136 - A PILOT OF ONLINE SURVEY SOFTWARE FOR EXPERT ELICITATION AT NICE

    Oct 1, 2018, 00:00

  • PMD34 - BUDGET IMPACT ANALYSIS (BIA) OF EMPLOYING A FEMALE EXTERNAL CATHETER (FEC) TO ASSIST WITH URINE OUTPUT MANAGEMENT (UOM) IN THE HOSPITAL SETTING

    Oct 1, 2018, 00:00

  • PSY99 - COST-EFFECTIVENESS OF TOCILIZUMAB + PREDNISOLONE COMPARED TO STANDARD OF CARE WITH PREDNISOLONE ALONE IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) IN TURKEY

    Oct 1, 2018, 00:00

  • PHP294 - A REVIEW OF RECENT APPRAISALS FROM THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW- HOW IMPORTANT IS THE ICER?

    Oct 1, 2018, 00:00

  • PDB137 - COMPARISON OF ORAL ANTIDIABETIC DRUGS AS ADD-ON TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON METFORMIN- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PIN130 - QUALITY OF LIFE OF ADULT PATIENTS UNDERWENT POLIOMYELITIS INFECTION DURING CHILDHOOD

    Oct 1, 2018, 00:00

  • PSY181 - 2018 UPDATE OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR NOVEL PSORIASIS AND PSORIATIC ARTHRITIS AGENTS- RESULTS, RATIONALE, AND TRENDS

    Oct 1, 2018, 00:00

  • PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIES

    Oct 1, 2018, 00:00

  • PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS6 - THE CLINICAL EFFECTIVENESS OF PROPHYLACTIC VERSUS SELECTIVE USE OF SURFACTANT IN PRETERM INFANTS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PUK33 - COMPARISON OF TREATMENT PATTERN IN UROLITHIASIS - A POPULATION STUDY USING KOREAN HEALTH INSURANCE REVIEW AND ASSESSMENT SERVICE DATABASE

    Oct 1, 2018, 00:00

  • PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?

    Oct 1, 2018, 00:00

  • PHP305 - CONSIDERING CHILDREN ALONGSIDE ADULTS IN NICE TECHNOLOGY APPRAISALS AND HIGHLY SPECIALISED TECHNOLOGIES EVALUATIONS

    Oct 1, 2018, 00:00

  • PMU31 - A REVIEW OF MANAGED ACCESS AGREEMENTS (MAAS) AND PATIENT ACCESS SCHEMES (PASS) IN ENGLAND

    Oct 1, 2018, 00:00

  • PSY156 - QUIDS IN? – A REVIEW OF WHETHER POTENTIAL BLOCKBUSTER SAVINGS FROM BIOSIMILAR ADALIMUMAB SHOULD BE REINVESTED IN OTHER DISEASE AREAS?

    Oct 1, 2018, 00:00

  • PHP155 - THE DEVELOPMENT AND EMPIRICAL APPLICATION OF A MULTIPLE SOCIETAL VALUE CRITERIA APPROACH TO RESOURCE ALLOCATION AMONG DISEASE CATEGORIES

    Oct 1, 2018, 00:00

  • PSY186 - CREATING AND MAINTAINING THE BULGARIAN CYSTIC FIBROSIS REGISTRY – NOT REALLY A MISSION IMPOSSIBLE

    Oct 1, 2018, 00:00

  • PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE- AN INTERNATIONAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM61 - LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PMU28 - A CROSS INDICATION BUDGET IMPACT ANALYSIS OF SECUKINUMAB- A GREEK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND133 - LIVING WITH MIGRAINE- THE IMPACT ON BRAZILIAN PATIENTS LIVES FROM MY MIGRAINE VOICE SURVEY

    Oct 1, 2018, 00:00

  • PCN198 - AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)

    Oct 1, 2018, 00:00

  • PMS27 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PRS15 - A 10-YEAR FOLLOW-UP OF A COHORT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THROUGH A ONE-WAY MARKOV MODEL

    Oct 1, 2018, 00:00

  • PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK- IDEGLIRA VERSUS IGLARLIXI

    Oct 1, 2018, 00:00

  • PHP181 - HEALTH TECHNOLOGY ASSESSMENT OF ONCOLOGY THERAPIES IN SPAIN AND ITALY- KEY METRICS AND CONSIDERATIONS

    Oct 1, 2018, 00:00

  • PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018)- NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORT

    Oct 1, 2018, 00:00

  • PRM69 - AN INCREASE OVER TIME IN PUBLISHED REAL-WORLD AND HEALTH ECONOMIC EVIDENCE IN CLINICAL JOURNALS ACROSS LYSOSOMAL STORAGE DISORDERS

    Oct 1, 2018, 00:00

  • PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE- A CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PCN385 - QUALITY OF LIFE OF PATIENTS LIVING WITH METASTATIC COLORECTAL CANCER (MCRC)- EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) QUESTIONNAIRE RESULTS FROM A REAL WORLD EUROPEAN SURVEY

    Oct 1, 2018, 00:00

  • PMU21 - ROLE OF PHARMACISTS FROM RESEARCH TO HEALTHCARE- AN IGNORE PARADIGM IN LOWER INCOME COUNTRY COUNTRY

    Oct 1, 2018, 00:00

  • PHP234 - EVALUATING THE IMPACT OF VALUE BASED PRICING (VBP) AND HTA ON PRICE LEVELS IN AN EU CONTEXT

    Oct 1, 2018, 00:00

  • PMD28 - VAGUS NERVE STIMULATION FOR TREATMENT-RESISTANT DEPRESSION- A BUDGET IMPACT ANALYSIS IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM117 - MULTI-COMPARATOR ICERS IN COST-EFFECTIVENESS ANALYSIS TO ACCOUNT FOR CHANGES IN CLINICAL PRACTICE AFTER THE INTRODUCTION OF A NEW TECHNOLOGY

    Oct 1, 2018, 00:00

  • PMD93 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TYPES OF MONOFOCAL INTRAOCULAR LENSES FOR CATARACT SURGERY IN RUSSIA

    Oct 1, 2018, 00:00

  • PND135 - FATIGUE IN MULTIPLE SCLEROSIS- ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE MFIS-5 QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PCV141 - MEDICATION ADHERENCE AND POTENTIAL DETERMINANTS FOR NON-ADHERENCE IN YOUNG AND MALE PATIENTS AT CVD RISK IN KOREA

    Oct 1, 2018, 00:00

  • PIN127 - HETEROGENEOUS PREFERENCES FOR HIV/AIDS COUNSELING AND TESTING AMONG TWO HIGH RISK POPULATIONS IN NORTHERN TANZANIA - RESULTS FROM A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PMU113 - TIME-DEPENDENT VARIATION OF PRO SCORES IN CHRONIC CONDITIONS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PMU118 - COGNITIVE DEBRIEFING INTERVIEW STUDIES TO INFORM PATIENT-REPORTED OUTCOME QUESTIONNAIRE DEVELOPMENT- A LITERATURE REVIEW AND SUGGESTED REPORTING GUIDELINES

    Oct 1, 2018, 00:00

  • PMS90 - A BONE RESORPTION MARKER TO MONITOR DRUG PROFILE IN PATIENTS WITH OSTEOPOROTIC FRACTURES

    Oct 1, 2018, 00:00

  • PRS94 - THE PARENTAL BURDEN OF CARING FOR A CHILD WITH PEANUT ALLERGY IN THE UK

    Oct 1, 2018, 00:00

  • PMD176 - MEDICATION ADHERENCE ASCERTAINED BY A DIGITAL OBSERVATIONAL STUDY APPROACH USING A MEDICAL APP- A PILOT STUDY AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON BETA-1B

    Oct 1, 2018, 00:00

  • HT2 - PATIENT CENTRIC MEASURES IN HTAS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PIN118 - KNOWLEDGE, ATTITUDE AND PRACTICES ABOUT ZIKA VIRUS AMONG PHARMACY STUDENTS IN THE UNITED STATES (US) AND INDIA- A CROSS SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PND1 - REVIEW OF THE LISTED SIDE EFFECTS OF MYASTHENIA GRAVIS TREATMENTS VERSUS THOSE RECORDED IN PUBLICATIONS

    Oct 1, 2018, 00:00

  • PSY161 - A RAPID LITERATURE REVIEW OF REAL-WORLD EVIDENCE IN MULTIPLE MYELOMA- PATIENT CHARACTERISTICS AND HEALTH OUTCOMES

    Oct 1, 2018, 00:00

  • PMH75 - PATIENT-REPORTED OUTCOMES IN PATIENTS WITH DEPRESSION- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PHP357 - MAKING SENSE FROM ANTI-SENSE- LESSONS IN TRANSLATING EXPEDITED REGULATORY APPROVAL INTO REIMBURSEMENT AND COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • PHP277 - HOW DO BELLWETHER HTA AGENCIES EVALUATE BIOSIMILARS?

    Oct 1, 2018, 00:00

  • PDB51 - RESULTS OF THE COSMODIA STUDY- ESTIMATING THE IMPACT ON THE NUMBER OF CLINICAL COMPLICATIONS AND THE ASSOCIATED POTENTIAL FINANCIAL BENEFIT AS A CONSEQUENCE OF BETTER MANAGEMENT OF GLYCAEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES IN ...

    Oct 1, 2018, 00:00

  • PHP147 - CHANGES IN THE NUMBER OF PHYSICIANS IN THE HEALTH CARE SYSTEM OF EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMD163 - HTA OF ARTIFICIAL URINARY SPHINCTER (AUS) FOR THE TREATMENT OF SEVERE MALE POST-PROSTATECTOMY INCONTINENCE IN ITALY

    Oct 1, 2018, 00:00

  • PSY149 - IQVIA PATIENT DATA ASSESSMENT- REAL WORLD EVIDENCE IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PIN74 - A SYSTEMATIC REVIEW ON ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION

    Oct 1, 2018, 00:00

  • PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING- IMPLICATIONS FOR RECRUITMENT

    Oct 1, 2018, 00:00

  • PMD146 - HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH ASEPTIC LOOSENING AFTER PRIMARY TOTAL KNEE ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PRM47 - UNDERSTANDING KEY VALUE DRIVERS OF A NOVEL TREATMENT IN MANAGEMENT OF FAMILIAL CHYLOMICRONEMIA SYNDROME

    Oct 1, 2018, 00:00

  • PDB42 - PRICE ANALYSIS OF ANTIDIABETIC DRUGS MARKETED IN ARABIC COUNTRIES

    Oct 1, 2018, 00:00

  • PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE- A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PHP330 - REAL-WORLD DATA COLLECTION ON MEDICAL DEVICES IN THE ERA OF VALUE-BASED HEALTHCARE- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM41 - ESTIMATION OF HOSPITAL COST SAVINGS ASSOCIATED WITH HYPOTENSION REDUCTION IN SEPTIC INTENSIVE CARE UNIT PATIENTS IN FRANCE

    Oct 1, 2018, 00:00

  • PCN322 - AN EXAMPLE OF RWE USED FOR HTA EVALUATION- ERLOTINIB RENEGOTIATION IN ITALY

    Oct 1, 2018, 00:00

  • PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIA

    Oct 1, 2018, 00:00

  • PND41 - HEALTHCARE COSTS OF PATIENTS WITH SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS- A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PND84 - PATIENT AND CAREGIVER BURDEN OF BOTULINUM TOXIN A INJECTIONS

    Oct 1, 2018, 00:00

  • PCV144 - EFFECT OF CONVENIENCE OF ORAL ANTICOAGULANT THERAPY ON MEDICATION ADHERENCE- RESULTS OF AN INTERNATIONAL STATED PREFERENCE SURVEY

    Oct 1, 2018, 00:00

  • PMU99 - PERCEPTIONS OF THE GREEK POPULATION CONCERNING MEDICINES – A DESCRIPTIVE ANALYSIS

    Oct 1, 2018, 00:00

  • PUK20 - COST-UTILITY ANALYSIS OF EXTRACORPOREAL LITHOTRIPSY VERSUS URETERORENOSCOPY-HOLMIUM LASER FOR TREATMENT OF URINARY STONES 20 MM.

    Oct 1, 2018, 00:00

  • PSY62 - DIRECT COST OFFSETS RELATED TO BELIMUMAB SUBCUTANEOUS ADMINISTRATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN SPAIN

    Oct 1, 2018, 00:00

  • PSY220 - IMPACT OF KERATOCONUS AND ITS TREATMENTS ON PATIENTS’ DAILY LIFE- QUALITATIVE PHASE OF THE DEVELOPMENT OF A QUALITY OF LIFE QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES

    Oct 1, 2018, 00:00

  • PSS5 - VISION-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH INTRAVITREAL AFLIBERCEPT- THE AQUA STUDY

    Oct 1, 2018, 00:00

  • PMH11 - E-THERAPIES IN PREVENTING AND TREATING EATING DISORDERS- REVIEW OF TRIALS AND REAL-WORLD EVIDENCE

    Oct 1, 2018, 00:00

  • PCV9 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR PEOPLE UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PRM67 - UTILITIES IN ONCOLOGY SUBMISSIONS SUBMITTED TO NICE —APPROACH OF THE MANUFACTURERS

    Oct 1, 2018, 00:00

  • PND131 - PATIENT PREFERENCES FOR DIFFERENT MODES AND FREQUENCY OF ADMINISTRATION OF MULTIPLE SCLEROSIS DISEASE MODIFYING THERAPIES

    Oct 1, 2018, 00:00

  • PRM217 - THE ONLINE VERSION OF EMPRO- A NEW PLATFORM SYSTEM FOR THE STANDARDIZED APPRAISAL OF PRO INSTRUMENTS.

    Oct 1, 2018, 00:00

  • PRM175 - EQ-5D-3L VS. EQ-5D-5L- A CROSS-SECTIONAL COMPARISON OF MEASUREMENT PROPERTIES AMONG TOTAL HIP AND KNEE REPLACEMENT PATIENTS

    Oct 1, 2018, 00:00

  • PDB1 - ACUTE RENAL OUTCOMES WITH SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS- REAL WORLD DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PMD61 - COST EFFECTIVENESS OF DERMABOND PRINEO SKIN CLOSURE SYSTEM IN HIP AND KNEE ARTHROPLASTY IN TURKEY

    Oct 1, 2018, 00:00

  • PHP237 - OVERVIEW OF GERMAN AMNOG DOSSIERS WITH PRICE ANALYSIS BEFORE AND AFTER EARLY BENEFIT ASSESSMENT

    Oct 1, 2018, 00:00

  • PCV68 - POTENTIAL SAVINGS IN HIGHEST PRESCRIBING REGIONS FOR DIRECT-ACTING ORAL ANTICOAGULANTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PND27 - COST IMPLICATIONS IN THE SELECTION OF FIRST LINE TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP116 - TREND IN OPIOID USE FROM 2001 THROUGH 2013 AMONG ELDERLY US VETERANS

    Oct 1, 2018, 00:00

  • PRM170 - UTILIZING PATIENT COLLAGES IN QUALITATIVE INTERVIEWS TO FACILITATE DATA COLLECTION IN PATIENTS DIAGNOSED WITH ULCERATIVE COLITIS

    Oct 1, 2018, 00:00

  • PHP81 - COMPARISON OF SELECTED DRUGS PRICES IN EU COUNTRIES

    Oct 1, 2018, 00:00

  • PMS63 - COST-EFFECTIVENESS OF ACTONEL® 35 MG (RISEDRONATE) GASTRO-RESISTANT TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE

    Oct 1, 2018, 00:00

  • PRM77 - VALIDATION OF COPD ICD10 DIAGNOSTIC CODES IN THE SIDIAP PRIMARY HEALTH CARE RESEARCH DATABASE USING A COMBINATION OF SPIROMETRY MEASURES, SYMPTOMS, DRUG USE, AND FREE TEXT REVIEW.

    Oct 1, 2018, 00:00

  • PRM255 - QUANTIFYING SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS- THE IN-SAMPLE METHOD

    Oct 1, 2018, 00:00

  • PSY187 - THE QUANTITY AND QUALITY OF EVIDENCE SUPPORTING EUROPEAN MARKETING AUTHORISATION OF ORPHAN DRUGS- COMPARISON OF RARE ONCOLOGY VERSUS RARE DISEASE

    Oct 1, 2018, 00:00

  • PHP117 - TRENDS OF PRESCRIPTION FOR OFF-LABEL DRUGS IN KOREAN PEDIATRIC PATIENTS USING CLAIMS DATA- WITH A FOCUS ON CLINICAL AREAS AND PRIMARY DISEASES

    Oct 1, 2018, 00:00

  • PHP100 - UTILIZATIONS AND EXPENDITURES OF TUMOR NECROSIS FACTOR ANTAGONISTS IN MEDICARE PART D- CROSS- SECTIONAL STUDY (2014-2015)

    Oct 1, 2018, 00:00

  • PUK10 - ANALYZING HEALTH-ECONOMIC EFFECTS OF A RENAL PRE-TRANSPLANT PATIENT-STRATIFICATION TOOL AT AN EARLY STAGE OF PRODUCT DEVELOPMENT

    Oct 1, 2018, 00:00

  • PCN180 - PHARMACOECONOMIC ASSESSMENT OF FULVESTRANT VERSUS DD (DOXORUBICIN, DOCETAXEL) THERAPY IN POSTMENOPAUSAL WOMEN WITH METASTATIC ER (+) HER2 (-) BREAST CANCER IN UKRAINE

    Oct 1, 2018, 00:00

  • PCV35 - SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE- DEFINITION OF POPULATION AND EVALUATION OF OUTCOMES USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PMD83 - CERVICAL CANCER SCREENING IN EUROPE - A SYSTEMATIC REVIEW ON COST EFFECTIVENESS STUDIES WITH SPECIFIC INTEREST ON RISK-ADAPTED STRATEGIES

    Oct 1, 2018, 00:00

  • PMU45 - ESTIMATING THE CLINICAL AND ECONOMIC BURDEN OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR HEART FAILURE

    Oct 1, 2018, 00:00

  • PHP232 - A COMPARISON OF COST-EFFECTIVENESS ASSESSMENTS BETWEEN NICE AND SMC TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • AD4 - ARE PATIENT-REPORTED PERSISTENCE AND ADHERENCE TO TREATMENT FOR A CHRONIC DISEASE VALID OUTCOMES? AN EXAMPLE WITH OSTEOPOROSIS

    Oct 1, 2018, 00:00

  • PIN8 - COMPARATIVE EFFICACY OF FIDAXOMICIN, VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS- COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?

    Oct 1, 2018, 00:00

  • PHP145 - NUMBER OF PHARMACISTS IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PSY143 - EPIDEMIOLOGY AND TREATMENT OF MICROSCOPIC COLITIS – REAL WORLD EVIDENCE FROM THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATION

    Oct 1, 2018, 00:00

  • PCV23 - TIME TO TREATMENT INTENSIFICATION IN NEW STATIN USERS

    Oct 1, 2018, 00:00

  • PND144 - REPORTED QUALITY OF LIFE IN PEOPLE WITH MULTIPLE SCLEROSIS UNDER LONG TERM TREATMENT WITH FAMPRIDINE

    Oct 1, 2018, 00:00

  • PCN223 - WHAT UNDERLIES THE OBSERVED HOSPITAL VOLUME-OUTCOME RELATIONSHIP?

    Oct 1, 2018, 00:00

  • PND33 - PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Oct 1, 2018, 00:00

  • PRM5 - PROFILING OF DISEASE SYMPTOMS AND ADVERSE EVENTS- DOES SOCIAL MEDIA AUGMENT TRADITIONAL APPROACHES?

    Oct 1, 2018, 00:00

  • PMS119 - ACCEPTABILITY OF HEALTH PROBLEMS IN CHRONIC MUSCULOSKELETAL DISEASES

    Oct 1, 2018, 00:00

  • PND35 - HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COST TRAJECTORIES IN FIVE YEARS FOLLOWING MS DIAGNOSIS- REGISTER-BASED PROSPECTIVE COHORT STUDIES IN SWEDEN

    Oct 1, 2018, 00:00

  • PHP206 - TUMOUR-AGNOSTIC AGENTS- ARE THEY FIT FOR REIMBURSEMENT?

    Oct 1, 2018, 00:00

  • PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS

    Oct 1, 2018, 00:00

  • PRM165 - INFLUENCE OF THE TIME HORIZON LENGTH ON THE RESULTS OF PHARMACOECONOMIC RESEARCH

    Oct 1, 2018, 00:00

  • PCV107 - MULTI-CRITERIA DECISION ANALYSIS (MCDA) - DISCUSSION ABOUT THE INCORPORATION OF RIOCIGUAT IN THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) UNDER THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)

    Oct 1, 2018, 00:00

  • PSY114 - COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH CONVENTIONAL THERAPY IN PATIENTS WITH CROHN’S DISEASE IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PCN217 - KEEPING UP WITH THE COMPARATORS- TRENDS IN TARGETED CANCER THERAPIES BECOMING RIGHT COMPARATORS FOR PAYERS

    Oct 1, 2018, 00:00

  • PMS18 - BUDGET IMPACT ANALYSIS OF KNEE OSTEOARTHRITIS VISCOSUPPLEMENTATION TREATMENT IN BRAZIL

    Oct 1, 2018, 00:00

  • QL1 - VALIDATION OF PROMIS PREFERENCE SCORE (PROPR) IN GERMAN PATIENTS WITH RHEUMATOLOGICAL CONDITIONS

    Oct 1, 2018, 00:00

  • PHP135 - CHANGES IN THE NUMBER OF DENTISTS IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES

    Oct 1, 2018, 00:00

  • PRM80 - THE USE OF EXTERNAL DATA TO BETTER INFORM SURVIVAL EXTRAPOLATIONS IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PRS49 - COST-EFFECTIVENESS OF THE FIXED-DOSE COMBINATION TIOTROPIUM + OLODATEROL VERSUS TIOTROPIUM BASED ON THE DYNAGITO TRIAL RESULTS IN FRANCE

    Oct 1, 2018, 00:00

  • PCN226 - BIOSIMILARS AND THE REGULATION OF ONCOLOGICAL PREPARATIONS IN GERMANY

    Oct 1, 2018, 00:00

  • PMS14 - CHILDHOOD OBESITY AND FRACTURE RISK- A REGION-WIDE LONGITUDINAL COHORT STUDY OF 466,000 CHILDREN AND UP TO 11 YEARS OF FOLLOW-UP

    Oct 1, 2018, 00:00

  • PSY29 - REAL-WORLD DISCONTINUATION OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS OVER THE FIRST 5 YEARS OF TREATMENT – A LITERATURE REVIEW OF DRUG SURVIVAL

    Oct 1, 2018, 00:00

  • PCP70 - REGENERATIVE MEDICINE- A PROPOSED CLASSIFICATION FOR HEOR BASED ON THERAPEUTIC STRATEGY AND TECHNOLOGY TYPE

    Oct 1, 2018, 00:00

  • PMD81 - COST EFFECTIVENESS ANALYSIS OF MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND FOR REFRACTORY PAINFUL BONE METASTASES

    Oct 1, 2018, 00:00

  • PMU1 - FREQUENCY OF REPORTABLE ADVERSE EVENTS IN HEALTH-RELATED SOCIAL MEDIA POSTS

    Oct 1, 2018, 00:00

  • PMD110 - COST-EFFECTIVENESS OF IMMUNOADSORPTION FOR INCOMPATIBLE KIDNEY TRANSPLANTATION IN GERMANY

    Oct 1, 2018, 00:00

  • PIN97 - VALIDATING DATA ON HEPATITIS C TESTING IN THE UK IN THE PRIMARY CARE SETTING

    Oct 1, 2018, 00:00

  • PSS36 - PHARMACOECONOMIC EVALUATION OF PHARMACOLOGICAL TREATMENT OPTIONS FOR PATIENTS WITH MODERATELY-SEVERE AND SEVERE PSORIASIS WITH BASE THERAPY RESISTANCE

    Oct 1, 2018, 00:00

  • PUK36 - COMPARISON OF PATIENT-REPORTED OUTCOMES IN RANDOMIZED CONTROLLED TRIALS AND IN OBSERVATIONAL STUDIES FOR OVERACTIVE BLADDER- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB15 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS- SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PDB111 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG DIABETES MELLITUS PATIENTS IN A NATIONAL HEALTH INSURANCE PROGRAM

    Oct 1, 2018, 00:00

  • PMU35 - COST COMPARISON OF COMPLEMENTARY AND ALTERNATIVE MEDICINE SPECIALIZED UNIT IN SUS

    Oct 1, 2018, 00:00

  • PCV92 - EARLY HEALTH TECHNOLOGY ASSESSMENT OF TISSUE-ENGINEERED HEART VALVES IN THE AORTIC POSITION IN ELDERLY PATIENTS

    Oct 1, 2018, 00:00

  • PCP46 - A SIMPLE DECISION TREE TO IDENTIFY POTENTIAL APPLICATIONS OF MACHINE LEARNING AS AN ADDITION TO TRADITIONAL STATISTICAL ANALYSIS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH

    Oct 1, 2018, 00:00

  • PDB67 - ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN PORTUGAL- A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON SUSTAIN 7

    Oct 1, 2018, 00:00

  • PND132 - ECONOMIC BURDEN OF MIGRAINE IN BRAZIL- RESULTS FROM MY MIGRAINE VOICE SURVEY

    Oct 1, 2018, 00:00

  • PMH20 - BUDGETARY IMPACT OF TREATING OPIOID ADDICTION IN THE DANISH MUNICIPAL SETTING

    Oct 1, 2018, 00:00

  • PCN261 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH COLORECTAL CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PUK3 - STUDY OF DIABETIC NEPHROPATHY PREVALENCE AMONG TYPE 2 DIABETIC OUTPATIENTS WITH UNCONTROLLED GLYCEMIA

    Oct 1, 2018, 00:00

  • PHP278 - GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT – WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?

    Oct 1, 2018, 00:00

  • PIN34 - COMPARING THE ESTIMATED PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF PHID-CV AND PCV-13 IN THE ROUTINE IMMUNISATION PROGRAMME IN GAVI-ELIGIBLE COUNTRIES (SUB-SAHARAN AFRICA AND ASIA/OCEANIA)- A MODELLING STUDY

    Oct 1, 2018, 00:00

  • PCN74 - A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

    Oct 1, 2018, 00:00

  • PRM129 - DECISION ANALYTIC MODELS TO INFORM ABOUT THE OPTIMAL MAMMOGRAPHY SCREENING INTERVALS- A SYSTEMATIC REVIEW.

    Oct 1, 2018, 00:00

  • PMD140 - OUT-OF-POCKET PAYMENTS FOR MEDICAL DEVICES AND EQUITY IN HEALTHCARE FOR PATIENTS WITH PRIMARY LYMPHEDEMA IN FRANCE

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59 (current)
  • 60
  • »